GSK plc (NYSE:GSK)
| 34.99 BATS BZX Real-Time Price As of 2:00pm ET |  -0.11 / -0.31%Today’s Change | 28.47 Today|||52-Week Range 43.70 | -0.43% Year-to-Date |
Latest GSK News | Press Releases
| GSK's Jemperli Effective Against First-Line Endometrial Cancer Mar 28 / Zacks.com - Paid Partner Content | GSK (GSK) Gains But Lags Market: What You Should Know Mar 21 / Zacks.com - Paid Partner Content |
| The company behind Johnnie Walker and Guinness appoints first female CEO Mar 28 / CNN.com | Better RSV Vaccine Stock: Pfizer, GSK, or Moderna? Mar 17 / MotleyFool.com - Paid Partner Content |
| GSK (GSK) Outpaces Stock Market Gains: What You Should Know Mar 27 / Zacks.com - Paid Partner Content | Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain? Mar 16 / Zacks.com - Paid Partner Content |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now Mar 27 / Zacks.com - Paid Partner Content | Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More Mar 16 / Zacks.com - Paid Partner Content |
| Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7% Mar 24 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 35.10 |
| Today’s open | 35.05 |
| Day’s range | 34.96 - 35.19 |
| Volume | 1,463,190 |
| Average volume (3 months) | 4,337,410 |
| Market cap | $70.4B |
Data as of 2:00pm ET, 03/29/2023
Growth & Valuation
| Earnings growth (last year) | +203.69% |
| Earnings growth (this year) | +33.75% |
| Earnings growth (next 5 years) | +10.30% |
| Revenue growth (last year) | -23.01% |
| P/E ratio | 13.0 |
| Price/Sales | 1.99 |
| Price/Book | 5.44 |
Competitors
Data as of 2:01pm ET, 03/29/2023
Financials
| Next reporting date | April 26, 2023 |
| EPS forecast (this quarter) | $0.85 |
| Annual revenue (last year) | $36.1B |
| Annual profit (last year) | $18.4B |
| Net profit margin | 15.21% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Middlesex, Greater London |
Forecasts
